Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | BUB1 | O43683 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.32 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28371753 | 1.00 | USP2 (0.34) | USP2SMN1; SMN2BUB1NR1H2NR1H3 | |
| SCHEMBL31751833 | 0.87 | USP2 (0.34) | USP2SMN1; SMN2BUB1NR1H2NR1H3 | |
| SCHEMBL6188259 | 0.86 | USP2 (0.38) | USP2SMN1; SMN2BUB1NR1H2NR1H3 | |
| SCHEMBL16594444 | 0.86 | USP2 (0.38) | USP2SMN1; SMN2BUB1NR1H2NR1H3 | |
| SCHEMBL15023539 | 0.85 | NR1H2 (0.34) | USP2SMN1; SMN2BUB1NR1H2NR1H3 | |
| SCHEMBL25330533 | 0.84 | GRIN2B (0.33) | USP2SMN1; SMN2BUB1NR1H2NR1H3 | |
| SCHEMBL502555 | 0.84 | GRIN2B (0.33) | USP2SMN1; SMN2BUB1NR1H2NR1H3 | |
| SCHEMBL705951 | 0.84 | GRIN2B (0.33) | USP2SMN1; SMN2BUB1NR1H2NR1H3 | |
| SCHEMBL3005261 | 0.84 | BUB1 (0.33) | USP2SMN1; SMN2BUB1NR1H2CHRM2 | |
| SCHEMBL25330541 | 0.84 | GRIN2B (0.33) | USP2SMN1; SMN2BUB1NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | USP2 499/4885SMN1; SMN2 3286/4885BUB1 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.